AIM ImmunoTech

AIM

시가총액 US$671만

CEO interview explores Ampligen's potential to extend survival and improve quality of life as AIM advances toward pivotal development

OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company's investigational dsRNA and highly selective TLR3 agonist immunomodulator.

Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program  Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program

Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration (the “FDA”) approval of daraxonrasib and outlining the Company's view of Ampligen's differentiated mechanism, clinical profile and potential role in the future treatment of pancreatic cancer.

Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition

Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom

OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.

Video webcast now available  here

Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge